This 2020 electron microscope image provided by the National Institute of Allergy and Infectious Diseases - Rocky Mountain Laboratories shows SARS-CoV-2 virus particles which cause COVID-19, isolated from a patient in the U.S., emerging from the surface of cells cultured in a lab. According to a study released in The Lancet Global Health on Wednesday, Oct. 27, 2021, Fluvoxamine, a cheap antidepressant, reduced the need for hospitalization among high-risk adults with COVID-19. (NIAID-RML via AP)
By Carla K. Johnson
A cheap antidepressant reduced the need for hospitalization among high-risk adults with COVID-19 in a study hunting for existing drugs that could be repurposed to treat coronavirus.
Researchers tested the pill used for depression and obsessive-compulsive disorder because it was known to reduce inflammation and looked promising in smaller studies.
They've shared the results with the U.S. National Institutes of Health, which publishes treatment guidelines, and they hope for a World Health Organization recommendation.
“If WHO recommends this, you will see it widely taken up,” said study co-author Dr. Edward Mills of McMaster University in Hamilton, Ontario, adding that many poor nations have the drug readily available. “We hope it will lead to a lot of lives saved.”
The pill, called fluvoxamine, would cost $4 for a course of COVID-19 treatment. By comparison, antibody IV treatments cost about $2,000 and Merck's experimental antiviral pill for COVID-19 is about $700 per course. Some experts predict various treatments eventually will be used in combination to fight the coronavirus.
Researchers tested the antidepressant in nearly 1,500 Brazilians recently infected with coronavirus who were at risk of severe illness because of other health problems, such as diabetes. About half took the antidepressant at home for 10 days, the rest got dummy pills. They were tracked for four weeks to see who landed in the hospital or spent extended time in an emergency room when hospitals were full.
In the group that took the drug, 11% needed hospitalization or an extended ER stay, compared to 16% of those on dummy pills.
The results, published Wednesday in the journal Lancet Global Health, were so strong that independent experts monitoring the study recommended stopping it early because the results were clear.
Questions remain about the best dosing, whether lower risk patients might also benefit and whether the pill should be combined with other treatments.
The larger project looked at eight existing drugs to see if they could work against the pandemic virus. The project is still testing a hepatitis drug, but all the others — including metformin, hydroxychloroquine and ivermectin — haven't panned out.
The cheap generic and Merck's COVID-19 pill work in different ways and “may be complementary,” said Dr. Paul Sax of Brigham and Women’s Hospital and Harvard Medical School, who was not involved in the study. Earlier this month, Merck asked regulators in the U.S. and Europe to authorize its antiviral pill.
___
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content.
In 2015, 193 parties signed the Paris Agreement. In doing so, they agreed to pursue efforts to limit the average global temperature increase to 1.5° Celsius - or 2.7 degrees Fahrenheit -above pre-industrial levels. To be clear, our planet is already 1.1 degrees hotter than it was 150 years ago. But most scientists agree that an increase of just .4 more degrees will drastically change the world. However, it would continue to be livable. Things do get murky, though, as the projections increase above that.
Dr. Jen Caudle, family physician and associate professor at Rowan University, joined Cheddar to break down how people can protect themselves and family amid the uncertainty of the new Omicron COVID-19 variant. Caudle emphasized the importance of getting vaccinated against COVID-19 with so much still uncertain about the pandemic. "We have to remember delta variant is still here in the United States," she said. "We're still losing too many people every single day to this virus."
Jill and Carlo discuss what appears to be the beginning of the end of Roe v. Wade, another victim dies following the school shooting in Michigan, Omicron in the U.S., Trump's Covid chronology and more.
Was it a coincidence that the omicron coronavirus variant evolved in a region with low vaccination rates? Cheddar speaks with epidemiologist Dr. Eric Feigl-Ding on the topic.
Astra founder, chairman, and CEO Chris Kemp spoke to Cheddar's Kristen Scholer about his company's first successful launch into orbit last month, becoming the fastest space company to reach orbit using a privately developed liquid-fueled rocket. He also noted that the company's priority is to "improve life on Earth from space" by rapidly increasing the number of low-orbiting satellites to do everything from connecting people to monitoring weather patterns.
Stocks closed at session lows Wednesday as investors grew skittish over the first reported case of the COVID-19 omicron variant in California. Josh Sailar, Partner at Blue Zone Wealth Advisors, joins Cheddar News' Closing Bell to discuss investor worry over the new variant, the Fed dropping the word 'transitory' to describe inflation and potentially speeding up their asset tapering timeline, 2022 predictions, and more.
As cases of the COVID-19 Omicron variant continue to pop up, including the first U.S. case in California, how will domestic holiday travel be impacted? That part of the travel sector has mostly recovered from the year-long pandemic rout, while business travel continues its slump. But could a new variant bring new lockdowns and domestic restrictions? Clint Henderson, Senior News Editor at The Points Guy, joins Cheddar News' Closing Bell to discuss what the omicron variant means for holiday travel, best practices for passengers traveling through airports, and more.
Over the Thanksgiving holiday, Elon Musk warned SpaceX employees in a leaked email that the company could be forced to file Chapter 11 bankruptcy if its raptor engine program fails. Musk then commented on the previous statement adding the detail that a recession could make such a bankruptcy possible.
